Related Experiment Video
Updated: May 30, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Determination of nifeviroc, a novel CCR5 antagonist: application to a pharmacokinetic study
Wei Wu1, Dong Xie, Zeneng Cheng
1School of Pharmaceutical Sciences, Central South University, Changsha 410013, China.
Abstract:
Nifeviroc is a novel CCR5 antagonist used for the treatment of HIV type-1 infection. A LC-ESI-MS/MS method for the determination of nifeviroc in human plasma was developed and validated. The calibration curve (r(2)=0.9993) of nifeviroc was established at the range of 1.924-2935 μg L(-1). The intra- and inter-day precisions (RSD%) were all less than 7%, and the accuracies at three concentration levels were all within 100 ± 5%. This validated method was then successfully applied to a pharmacokinetic study in health Chinese volunteers.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Inhibitors Of Virion Release

